Home / Resources / Pharma R&D Annual Review 2024 Supplement: New Active Substances Launched During 2023

Pharma R&D Annual Review 2024 Supplement: New Active Substances Launched During 2023

Report
Clinical
Preview Report Cover for Pharma R&D Annual Review 2024 Supplement: New Active Substances Launched During 2023

In 2023, the pharmaceutical industry saw 91 NASs — 17 more than 2022, a significant boost — across 90 products (one product was a fixed-dose combination containing two NASs) making their market debuts. It was the second-best year ever in terms of the number of NAS launches.

In the evolving landscape of cancer treatment, targeted therapies continue to be a transformative technology driving innovation.
Steve Worland, CEO, eFFECTOR Therapeutics
Related products
Getting the full drug RandD landscape
Pharmaprojects
世界的な医薬品研究開発の状況を追跡し、分析するための業界標準
Surfacing insights for a successful clinical trial
Trialtrove
臨床試験の戦略、設計、実施のための頼りになる情報リソース
Analyst visualizing the drug development process on screen
Biomedtracker
医薬品開発パイプラインのリアルタイム追跡と分析

Related resources

Citeline Clinical Infographic: A Promising Rebound Selected Insights from the Annual Clinical Trials Roundup: 2024 Edition
OCT 10, 2024
Infographic
Clinical

The Annual Clinical Trials Roundup 2024 Edition: Promising Road to Recovery

The rebound in clinical trial starts in 2023 signals a return to form after last year’s decline.

A variety of pills and tablets arranged neatly on a wooden table surface
OCT 09, 2024
Report
商業化支援サービス

Key Potential Drug Launches in 2025

Biomedtracker’s Key Potential Drug Launches in 2025 report provides a longer-term look at some key late-stage drugs projected to hit the market in 2025.

AI
OCT 11, 2024
Whitepaper
Clinical

AI in Pharma: Benefits, Risks, and the Road Ahead

AI is being used to streamline and accelerate each step of the drug development process from research through approval and marketing.

View all